Hoffmann-La Roche

Quick facts

Marketed products

• 5-Fluouracil · Oncology
  5-Fluorouracil is a pyrimidine analog that inhibits thymidylate synthase and gets incorporated into RNA and DNA, disrupting nucleotide synthesis and causing cancer cell death.
• Actos · Other
• antihistamine · Other
• Background ARVs · Infectious Disease / Virology
  Background ARVs are antiretroviral drugs that suppress HIV replication through various mechanisms including reverse transcriptase inhibition, protease inhibition, and integrase inhibition.
• calcipotriol hydrate [Daivonex] · Dermatology
  Calcipotriol is a vitamin D3 analog that binds to the vitamin D receptor to regulate skin cell differentiation and proliferation, reducing excessive keratinocyte growth.
• CNI (50%) · Immunology
  CNI (calcineurin inhibitor) suppresses T-cell activation by inhibiting calcineurin phosphatase, thereby reducing production of pro-inflammatory cytokines.
• CNI (≥75%) · Immunology
  CNI (calcineurin inhibitor) suppresses T-cell activation by inhibiting calcineurin phosphatase, thereby blocking IL-2 production and T-cell proliferation.
• Copegus · Other
• Copegus (ribavirin) · Virology/Infectious Disease
  Ribavirin is a nucleoside analog that inhibits viral RNA synthesis by interfering with the viral polymerase and depleting guanosine nucleotide pools.
• Corticosteroid or NSAID · Immunology, Rheumatology, Pain Management
  Corticosteroids suppress immune and inflammatory responses by binding glucocorticoid receptors, while NSAIDs inhibit cyclooxygenase enzymes to reduce prostaglandin production and inflammation.
• Corticosteroids, IV · Immunology, Rheumatology, Endocrinology
  Corticosteroids suppress immune and inflammatory responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.
• Corticosteroids, PO
• CSs · Immunology / Inflammation
  CSs likely refers to corticosteroids, which suppress immune and inflammatory responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.
• DT · Immunology / Infectious Disease Prevention
  DT is a diphtheria and tetanus toxoid vaccine that stimulates the immune system to produce antibodies against diphtheria and tetanus toxins.
• enfuvirtide [Fuzeon]
• epoetin beta [NeoRecormon] · Hematology
  Epoetin beta is a recombinant erythropoietin that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells.
• Erlotinib [Tarceva]
• FEC · Oncology
  FEC is a combination chemotherapy regimen that uses three cytotoxic agents to damage cancer cell DNA and inhibit cell division.
• FUZEON [enfuvirtide] · Infectious Disease / Virology
  Enfuvirtide blocks HIV from entering CD4+ T cells by binding to the gp41 fusion protein on the viral envelope and preventing membrane fusion.
• ibandronate [Bonviva/Boniva] · Bone metabolism / Osteoporosis
  Ibandronate is a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and blocking the mevalonate pathway in osteoclasts.
• Izervay™ · Ophthalmology
  Izervay is a complement C3 inhibitor that blocks the central complement pathway to reduce inflammation and tissue damage in retinal diseases.
• Lamivudine (LAM) · Infectious Disease
  Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that blocks HIV and hepatitis B virus replication by inhibiting the reverse transcriptase enzyme.
• Methotrexate (stable dose) · Oncology; Immunology; Rheumatology
  Methotrexate inhibits dihydrofolate reductase, blocking the synthesis of purines and pyrimidines required for DNA replication and cell division.
• Methotrexate (tapering dose) · Oncology, Immunology, Rheumatology
  Methotrexate inhibits dihydrofolate reductase, blocking the synthesis of purines and pyrimidines required for DNA replication and cell division.
• Mycophenolate mofetil, adjusted dose
• Mycophenolate mofetil, Standard dose · Immunology
  Mycophenolate mofetil inhibits inosine monophosphate dehydrogenase (IMPDH), selectively suppressing T and B lymphocyte proliferation to prevent organ rejection and autoimmune responses.
• non-biological DMARDs · Immunology
  Non-biological DMARDs are small-molecule drugs that suppress the immune system by inhibiting intracellular signaling pathways to reduce inflammation and joint damage in autoimmune diseases.
• NSAIDs
• OCR · Contraception / Gynecology
  OCR is an oral contraceptive containing ethinylestradiol and norgestimate that prevents pregnancy by suppressing ovulation and altering cervical mucus.
• Optimized background ARV · Infectious Disease / Virology
  Optimized background ARV refers to a tailored combination of antiretroviral drugs selected based on individual patient resistance testing and treatment history to maximize viral suppression in HIV infection.
• PEG-IFN alfa-2a
• Peg-Interferon Alpha-2A
• Phesgo · Other
• PI · Virology/Infectious Disease
  PI is a protease inhibitor that blocks viral protease activity, preventing the maturation and replication of viruses.
• Placebo matched to prednisone
  A placebo formulation designed to match the appearance and administration route of prednisone for use as a control in clinical trials.
• Placebo to adalimumab
  Placebo is an inert substance with no active pharmacological mechanism.
• Placebo to Mycophenolate mofetil · Immunology; Transplantation
  Mycophenolate mofetil is an immunosuppressant that selectively inhibits inosine monophosphate dehydrogenase (IMPDH), reducing proliferation of T and B lymphocytes.
• Placebo to tocilizumab · Immunology
  Tocilizumab is a monoclonal antibody that blocks the interleukin-6 (IL-6) receptor, inhibiting the pro-inflammatory IL-6 signaling pathway.
• Prednisone/Prednisolone/Methylprednisolone · Immunology, Rheumatology, Endocrinology, Oncology (supportive care)
  Prednisone, prednisolone, and methylprednisolone are corticosteroids that bind to glucocorticoid receptors in the cytoplasm, translocate to the nucleus, and suppress inflammatory gene expression and immune cell activation.
• rituximab [MabThera/Rituxan] · Oncology, Immunology
  Rituximab is a monoclonal antibody that binds to CD20 on B cells, marking them for destruction by the immune system.

Phase 3 pipeline

• 23-PPV · Immunology / Infectious Disease
  23-PPV is a pneumococcal polysaccharide vaccine that stimulates the immune system to produce antibodies against 23 serotypes of Streptococcus pneumoniae.
• Alectnib · Other
• aleglitazar+metformin · Diabetes
  Aleglitazar, a PPARα/γ agonist, and metformin, a biguanide, work together to improve insulin sensitivity and glucose uptake in the body.
• Alimta or Taxotere
• anti-IL-2R · Immunology
  anti-IL-2R drugs target the interleukin-2 receptor to prevent T-cell activation.
• Anti-VEGF Therapy · Oncology, Ophthalmology
  Anti-VEGF therapy blocks vascular endothelial growth factor (VEGF), a key signaling protein that promotes abnormal blood vessel formation in tumors and certain eye diseases.
• aPCC · Hematology
  aPCC is an anticoagulant that works by replacing and controlling the activity of natural anticoagulant proteins in the blood.
• Baseline Treatment · Oncology
  Baseline treatment is a type of therapy that aims to establish a standard level of treatment for a particular disease or condition.
• Becavizumab · Other
• bitopertin [RO4917838] · Psychiatry
  Bitopertin is a glycine receptor antagonist.
• bitopertin [RO4917838] level 1 · Psychiatry/Neurology
  Bitopertin is a glycine transporter 1 (GlyT1) inhibitor that increases synaptic glycine levels to enhance NMDA receptor function in the brain.
• bitopertin [RO4917838] level 2 · Psychiatry
  Bitopertin is a glycine receptor antagonist.
• Bypassing Agents · Hematology
  Bypassing agents are coagulation factors that activate the coagulation cascade downstream of factors VIII and IX to restore thrombin generation in patients with inhibitors to these factors.
• CDK4/6i · Oncology
  CDK4/6 inhibitors block cyclin-dependent kinases 4 and 6, which prevents phosphorylation of the retinoblastoma protein and halts cell cycle progression in G1 phase.
• Dalcetrapib (RO4607381) · Cardiovascular
  Dalcetrapib inhibits cholesteryl ester transfer protein (CETP) to increase HDL cholesterol and reduce LDL cholesterol levels.
• Desloratadine given orally · Allergy/Immunology
  Desloratadine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses without significant central nervous system penetration.
• Dexamethasone given orally · Immunology, Rheumatology, Oncology (supportive care), Endocrinology
  Dexamethasone is a synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors in the cytoplasm.
• dexpantenol [Bepantol] · Dermatology
  Dexpantenol is a topical antiviral agent that works by inhibiting the replication of certain viruses.
• Diphenhydramine IV · Allergy/Immunology
  Diphenhydramine is a first-generation antihistamine that blocks H1 histamine receptors to reduce allergic and inflammatory responses.
• Disease-modifying anti-rheumatic drugs · Immunology / Rheumatology
  Disease-modifying anti-rheumatic drugs (DMARDs) suppress the underlying immune-mediated inflammatory processes that drive rheumatoid arthritis and other autoimmune conditions.
• Epirubicine · Other
• epoetin alfa or beta · Oncology
  Epoetin alfa and beta stimulate erythropoiesis by binding to the erythropoietin receptor.
• erythromycin [Eritex] · Infectious diseases
  Erythromycin inhibits protein synthesis by binding to the 50S subunit of the bacterial ribosome.
• Etrozulimab · Other
• Evidence-based medical care for Acute Coronary Syndrome
• Factor VIII (FVIII) · Hematology
  Factor VIII is a clotting factor that replaces deficient or dysfunctional coagulation factor VIII to restore blood clotting ability in hemophilia A patients.
• FAP IL2V · Oncology
  FAP IL2V is a bispecific immunotherapy that targets fibroblast activation protein (FAP) on cancer-associated fibroblasts while delivering interleukin-2 (IL-2) to activate anti-tumor immune responses.
• FDC of Pertuzumab and Trastuzumab SC · Oncology
  This fixed-dose combination of two monoclonal antibodies blocks HER2 signaling by targeting the HER2 receptor from different epitopes, preventing tumor cell growth and survival.
• FEC Chemotherapy · Oncology
  FEC is a combination chemotherapy regimen that uses three cytotoxic agents to damage cancer cell DNA and inhibit cell division.
• Fisiogel · Other
• Fluoropyrimidine-based Chemotherapy · Oncology
  Fluoropyrimidine-based chemotherapy inhibits thymidylate synthase and incorporates into DNA/RNA to disrupt cancer cell replication and survival.
• Folic acid or folate · Nutritional supplementation / Hematology / Obstetrics
  Folic acid acts as a coenzyme in one-carbon transfer reactions essential for DNA synthesis and cell division.
• fusidic acid [Verutex] · Infectious diseases
  Fusidic acid inhibits bacterial protein synthesis by binding to the elongation factor G.
• Herceptin IV [trastuzumab] · Oncology
  Trastuzumab is a monoclonal antibody that binds to HER2 receptors on cancer cells, blocking growth signals and triggering immune-mediated cell death.
• Herceptin SC [trastuzumab] · Oncology
  Trastuzumab is a monoclonal antibody that binds to HER2 receptors on cancer cells, blocking growth signals and triggering immune-mediated cell death.
• Hormone Therapy · Endocrinology
  Hormone therapy replaces or modulates endogenous hormones to treat deficiency states or hormone-sensitive conditions.
• interferon-a-2a · Oncology
  Interferon-alpha-2a works by stimulating the body's immune system to fight viral infections and cancer.
• Interferon alfa 2a [Roferon] · Oncology, Immunology, Virology
  Interferon alfa-2a activates the immune system by binding to interferon-alpha receptors on cell surfaces, enhancing natural killer cell and macrophage activity to fight viral infections and cancer cells.
• MabThera/Rituxan · Oncology, Immunology
  Rituximab is a monoclonal antibody that binds to CD20 on B cells, marking them for destruction by the immune system.
• Mycophenoate Mofetil · Immunology
  Mycophenolate mofetil inhibits inosine monophosphate dehydrogenase (IMPDH), selectively suppressing T and B lymphocyte proliferation to prevent immune rejection.

Phase 2 pipeline

• Activated Prothrombin Complex Concentrate · Hematology
  Activated Prothrombin Complex Concentrate works by replacing clotting factors to help the blood to clot.
• Ado-trastuzumab emtamsine · Oncology
  Ado-trastuzumab emtansine is a HER2-targeting antibody-drug conjugate that delivers a cytotoxic agent to HER2-positive cancer cells.
• ANA598 · Infectious Diseases
  ANA598 is a non-nucleoside inhibitor of the NS5B polymerase of the hepatitis C virus.
• Anti-EGFR-Containing Regimen · Oncology
  Inhibits the epidermal growth factor receptor (EGFR)
• antibody induction
• Bevacizumab-containing regimen · Oncology
  Bevacizumab-containing regimens work by inhibiting angiogenesis through the blockade of vascular endothelial growth factor A (VEGF-A).
• Biological DMARDs · Immunology
  Biological DMARDs work by targeting specific proteins involved in the immune response to reduce inflammation and slow disease progression.
• C.E.R.A. · Oncology
  C.E.R.A. is a continuous erythropoietin receptor activator.
• Carboplatin-based chemotherapy · Oncology
  Platinum-based DNA alkylating agent
• Concomitant Bevacizumab
• Diphenhydramine hydrochloride or alternative antihistamine
• Doxycline · Other
• DPP-IV Inhibitor · Diabetes
  DPP-IV inhibitors block the action of dipeptidyl peptidase-4, an enzyme that breaks down incretin hormones, thereby increasing incretin levels and enhancing glucose-dependent insulin secretion.
• Dual Integrin Antagonist
• eloxatin · Other
• Epidoxorubicin · Oncology
• Erlotinib, escalating dose
• Erlotinib, standard dose · Oncology
  Erlotinib is a tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR) tyrosine kinase.
• First line chemotherapy
• FOLFOX induction regimen · Oncology
  Oxaliplatin inhibits DNA replication by binding to DNA and inducing DNA damage.
• FVIII Replacement · Rare Disease
  Recombinant FVIII replacement to correct FVIII deficiency
• GC33 · Diabetes
  GC33 is a small molecule that targets the SGLT2 receptor.
• Glucocorticoid Agent
• methoxy polyethylene glycol-ep [Mircera]
• Methoxy-polyethyleneglycol epoetin beta
• Metronidazole Actavis
• Ocrelizumab Reference Formulation
• Ocrelizumab Test Formulation
• Optimized background ARV therapy
• Optimized Background ARVs
• Other Biologics
• PRM-151
• RAR Gamma
• Recombinant Interferon Alfa 2a
• RG1662
• RG7314
• RG7774
• Ro 205-2349
• RO4588161
• RO4602522

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Hoffmann-La Roche portfolio CI brief
• Hoffmann-La Roche pipeline updates RSS